Carmell Therapeutics Corporation (CTCX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Carmell Therapeutics Corporation (CTCX) has a cash flow conversion efficiency ratio of 0.198x as of March 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-752.95K) by net assets ($-3.81 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See net asset quality index of Carmell Therapeutics Corporation to measure how much of total assets are equity-financed.
Carmell Therapeutics Corporation - Cash Flow Conversion Efficiency Trend (2021–2024)
This chart illustrates how Carmell Therapeutics Corporation's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check CTCX cash flow quality score to evaluate the quality of earnings relative to operating cash generation.
Carmell Therapeutics Corporation Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Carmell Therapeutics Corporation ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Picton Property Income Ltd
LSE:PCTN
|
0.018x |
|
Jain Irrigation Systems Limited
NSE:JISLDVREQS
|
0.032x |
|
Sentral Mitra Informatika Tbk PT
JK:LUCK
|
-0.026x |
|
Cardio Diagnostics Holdings Inc
NASDAQ:CDIO
|
-0.195x |
|
Biomerica Inc
NASDAQ:BMRA
|
-0.377x |
|
PLENUM AG NA O.N.
F:PLEK
|
N/A |
|
Sentage Holdings Inc
NASDAQ:SNTG
|
-0.060x |
|
Alpha Compute Corp
NASDAQ:ALP
|
-0.080x |
Annual Cash Flow Conversion Efficiency for Carmell Therapeutics Corporation (2021–2024)
The table below shows the annual cash flow conversion efficiency of Carmell Therapeutics Corporation from 2021 to 2024. For the full company profile with market capitalisation and key ratios, see Carmell Therapeutics Corporation (CTCX) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-4.71 Million | $-4.39 Million | 0.931x | +376.10% |
| 2023-12-31 | $24.75 Million | $-8.35 Million | -0.337x | -471.78% |
| 2022-12-31 | $-37.79 Million | $-3.43 Million | 0.091x | +128.03% |
| 2021-12-31 | $-29.58 Million | $-1.18 Million | 0.040x | -- |
About Carmell Therapeutics Corporation
Carmell Corporation operates as a bio-aesthetics company. The company utilizes Carmell Secretome to support skin and hair health. Its Carmell Secretome consists of growth factors and proteins extracted from allogeneic human platelets sourced from tissue banks. The company also developed a microemulsion formulation that enables delivery of lipophilic and hydrophilic ingredients without relying on … Read more